Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomics of anthracycline-cyclophosphamide-taxane chemotherapy: an influence of CYP polymorphisms and BMI on breast cancer treatment outcomes.

Pharmacogenomics - 1 Jan 2025

Mistry Tanuma, Nath Partha, Alam Neyaz, Nasare Vilas D

Abstract excerpt

AIMS: Sequential Anthracycline-Taxane chemotherapy is standard treatment for BC. This study examines the combined impact of low BMI and CYP polymorphisms on treatment response. METHOD: BMI was assessed before chemotherapy, and clinical response was evaluated using RECIST v.1. Four SNPs in CYP2C9, CYP2C19, and CYP3A4 gene were analyzed in 148 samples using PCR-RFLP. RESULTS: CYP2C19 (G681A) was significantly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anthracyclines
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bridged-Ring Compounds

Share to Cyclophosphamide

Share to Cytochrome P-450 CYP2C19

Share to Cytochrome P-450 CYP3A

Share to Pharmacogenetics

Share to Taxoids

Source

Open in PubMed Open full text

Identifiers

PMID: 41328687
DOI: 10.1080/14622416.2025.2593225
PMCID: PMC12959188

Genes

CYP2C19
CYP2C9
CYP3A4

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomics of anthracycline-cyclophosphamide-taxane chemotherapy: an influence of CYP polymorphisms and BMI on breast cancer treatment outcomes.PMID 41328687Read ↗

Impact of low BMI and ABCC2 genotype on the clinical response of sequential anthracycline-taxane chemotherapy receiving breast cancer patients: a hospital-based study.Semantic proximity Read ↗

CYP2C8 rs11572080 and CYP3A4 rs2740574 risk genotypes in paclitaxel-treated premenopausal breast cancer patients.Semantic proximity Read ↗

Toxicity and Pharmacogenomic Biomarkers in Breast Cancer ChemotherapySemantic proximity Read ↗

Breast Cancer Susceptibility: Meta-Analysis of Cytochrome P450 2C19 (CYP2C19) and Estrogen Receptor-1 (ESR1) Genetic Variants.Semantic proximity Read ↗

Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review.Semantic proximity Read ↗

Novel molecular biomarkers associated with Taxane-induced toxicities in women with breast cancer from the Brazilian Amazon.Semantic proximity Read ↗

The CYP19A1 rs700519 Polymorphism and Breast Cancer Susceptibility in China: A Case-Control Study and Updated Meta-Analysis.Semantic proximity Read ↗

The Effect of CYP2C19*2 (rs4244285) and CYP17 (rs743572) SNPs on Adriamycin and Paclitaxel based Chemotherapy Outcomes in Breast Cancer Patients.Semantic proximity Read ↗

Pharmacogenetics as a Future Tool to Risk-Stratify Breast Cancer Patients According to Chemotoxicity Potential from the Doxorubicin Hydrochloride and Cyclophosphamide (AC) RegimenSemantic proximity Read ↗

Association between CYP19 polymorphisms and breast cancer risk: results from 10,592 cases and 11,720 controls.Semantic proximity Read ↗

Analysis of CYP17, CYP19 and CYP1A1 Gene Polymorphisms in Iranian Women with Breast Cancer.Semantic proximity Read ↗

Evaluation of association studies and a systematic review and meta-analysis of CYP1A1 T3801C and A2455G polymorphisms in breast cancer risk.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.